Krystal Biotech, Inc. $KRYS Stock: Torray Investment Partners LLC Decreases Position

Key Points

• Torray Investment Partners cut its Krystal Biotech stake by 31.1% in the third quarter, selling 3,786 shares and retaining 8,370 shares valued at about $2.78 million.
• Institutional investors own 86.29% of KRYS, while company insiders own 13.10%; a director and an insider each reported selling 25,000 shares.
• Krystal Biotech beat quarterly earnings and revenue estimates, and analysts’ consensus rating was “Moderate Buy,” with an average price target of $375.

Torray Investment Partners LLC trimmed its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 31.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,370 shares of the company's stock after selling 3,786 shares during the period. Torray Investment Partners LLC's holdings in Krystal Biotech were worth $2,784,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KRYS. BlackRock Inc. bought a new position in shares of Krystal Biotech during the 2nd quarter valued at approximately $1,554,113,000. William Blair Investment Management LLC bought a new stake in Krystal Biotech in the second quarter worth $211,909,000. First Trust Advisors LP lifted its position in Krystal Biotech by 42.9% in the first quarter. First Trust Advisors LP now owns 350,521 shares of the company's stock worth $90,547,000 after buying an additional 105,245 shares during the last quarter. Janus Henderson Group PLC lifted its position in Krystal Biotech by 21.5% in the first quarter. Janus Henderson Group PLC now owns 266,659 shares of the company's stock worth $68,879,000 after buying an additional 47,219 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Krystal Biotech by 36.6% during the first quarter. Bank of America Corp DE now owns 260,647 shares of the company's stock worth $67,330,000 after buying an additional 69,840 shares during the period. 86.29% of the stock is owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, Director Dino A. Rossi sold 25,000 shares of the company's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Price Performance

Shares of KRYS opened at $305.03 on Wednesday. The company has a 50-day moving average of $335.72 and a 200 day moving average of $308.77. Krystal Biotech, Inc. has a 1-year low of $192.52 and a 1-year high of $382.54. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of 40.15 and a beta of 0.56.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The firm had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 7.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KRYS. Jefferies Financial Group reiterated a "buy" rating and set a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Citigroup lowered their target price on shares of Krystal Biotech from $416.00 to $412.00 and set a "buy" rating for the company in a report on Tuesday. HC Wainwright restated a "buy" rating and issued a $361.00 target price on shares of Krystal Biotech in a report on Thursday, October 15th. Bank of America lifted their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, September 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They set a "buy" rating and a $441.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Krystal Biotech has an average rating of "Moderate Buy" and an average target price of $375.00.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Third-quarter EPS was $2.05, above estimates, while revenue of $127.34 million also topped forecasts and grew about 30% year over year. Vyjuvek strength supported the results. Krystal Biotech Q3 results
• Positive Sentiment: The company announced a $400 million share-repurchase program over two years, which may support demand for the shares. Share repurchase announcement
• Neutral Sentiment: Citigroup, TD Cowen and RBC lowered their price targets, but continued to rate KRYS Buy or Outperform, indicating continued optimism alongside more cautious valuation assumptions. RBC assessment
• Negative Sentiment: Pipeline timelines have slipped into 2027, delaying potential development milestones. Quarterly EPS also declined from $2.66 a year earlier, despite beating analyst estimates, contributing to a cautious reaction to the earnings news. Results and pipeline update

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.